





Optilume® Stricture Order Numbers

		Balloon Length (3cm)	Balloon Length (5cm)
Inflated Balloon Diameter (Fr)	Content	Product SKU	Product SKU
 18.0	Optilume® Urethral Drug Coated Balloon & Inflation Device	OPTBDL7000B	OPTBDL7001B
 24.0	Optilume® Urethral Drug Coated Balloon & Inflation Device	OPTBDL7002B	OPTBDL7003B
 30.0	Optilume® Urethral Drug Coated Balloon & Inflation Device	OPTBDL7004B	OPTBDL7005B
 36.0	Optilume® Urethral Drug Coated Balloon & Inflation Device	OPTBDL7006B	OPTBDL7007B
Optilume® Urethral Drug Coated Balloon/ Basic Balloon Inflated Diameter (Fr)	Content	Product SKU	Product SKU
 24.0 / 18.0	Optilume® Urethral Drug Coated Balloon, Basic Balloon (3cm) & Inflation Device	OPTBDL7008B	OPTBDL7009B
 30.0 / 24.0	Optilume® Urethral Drug Coated Balloon, Basic Balloon (3cm) & Inflation Device	OPTBDL7010B	OPTBDL7011B

Reimbursement

The Optilume® Stricture Balloon, used for treating anterior urethral strictures, has been **issued Category 1 CPT Code 52284** by the American Medical Association (AMA). This code facilitates reimbursement by public and private health insurance payers in the United States¹. Additionally, the Centers for Medicare & Medicaid Services (CMS) have provided national average reimbursement rates for the procedure in various settings, such as physician offices, hospital outpatient departments, and ambulatory surgery centers.

1 DeLong J, et al. Outcomes of Bulbar Urethral Stricture Treatment With Optilume: ROBUST I Study Results. J Urol. 2025 Jan;213(1):90-8. 2 Srikanth, P, DeLong, J., Virasoro, R., & Elliott, S. P. (2025). A drug-coated balloon treatment for urethral stricture disease: Three-year results from the ROBUST III study. Journal of Endourology, 39(5), 567–574.

* This information is provided by Laborie for reimbursement informational purposes only. This is not an affirmative instruction as to which codes and modifiers to use for a particular service or item. Any coding, coverage, and payment information contained herein is gathered from various resources and is subject to change without notice. It is always the provider's responsibility to determine medical necessity, the proper site for delivery of any services and to submit appropriate codes, charges, and modifiers for services that are rendered. Laborie recommends that you consult with your payers, reimbursement specialists and/or legal counsel regarding coding, coverage and reimbursement matters.


Please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use. The Optilume® DCB is indicated for use in patients with obstructive urinary symptoms associated with anterior urethral stricture. It is designed to be used in adult males for anterior urethral strictures of ≤3cm in length. The Optilume® DCB is contraindicated for patients with known hypersensitivity to paclitaxel or structurally related compounds and patients with urologic implants such as penile implants or artificial urinary sphincters. Paclitaxel may be present in semen after treatment with the Optilume® DCB. The risks associated with paclitaxel in semen and the impact on sperm and spermatogenesis are unknown. Men should abstain or use a condom for 30 days and men with partners of child-bearing potential should use highly effective contraceptive and avoid fathering children for 6 months after treatment. Monitor for signs of anaphylaxis or hypersensitivity to paclitaxel. Potential risks can include, but are not limited to, the following: blood in the urine (hematuria), painful urination (dysuria), urinary tract infection (UTI), and urinary retention.

©2025 Laborie. All rights reserved.
Manufactured by Urotronic, Inc.



Optilume® Stricture

Minimally-invasive treatment
for anterior urethral strictures



A Simple, Proven,
and Durable Solution
for Stricture Relief



USA
T +1 800 522 6743
E usmarketing@laborie.com
W optilume.com/stricture

To incorporate Optilume® Stricture
into your practice, please visit us at
www.optilume.com



Learn more

MKT-00904 [A]




Simple. Proven. Durable.

The treatment that's transforming urethral stricture disease

Traditionally patients suffering from anterior urethral strictures have limited options which provide temporary relief. When these treatments fail it requires repeated dilation with diminishing results, ongoing self-catheterization, or invasive reconstructive surgery.

Optilume® Stricture provides a different option: a drug coated balloon treatment that dilates the urethral lumen and delivers paclitaxel directly into the tissue, significantly reducing the incidence of stricture.^{1,2}


Optilume® Stricture is more than just a treatment—it's a breakthrough in stricture management. By combining mechanical dilation for immediate symptom relief with localized drug delivery, Optilume® Stricture not only opens the urethra but actively works to reduce stricture recurrence. This first-of-its-kind technology disrupts the cycle of repeat procedures, offering a minimally invasive, durable, and cost-effective solution for patients globally.^{1,2}




“The very first 24 hours, I felt a noticeable difference. **Right from the first day** I felt completely changed.”

Brett H, Patient, age 40


A **simple** procedure for significant relief^{1,2}



1 Insert drug-coated balloon into the urethral lumen.



2 The balloon expands the lumen, creating **microfissures** in the tissue.



3 The balloon's coating releases paclitaxel directly into the fissured tissue. Paclitaxel is absorbed by the urothelium, where it resides through 28 days, reducing cell proliferation and fibrotic scar tissue generation.

“...**my standard of care** now is an Optilume balloon up-front. Because it has the same chance of success as urethroplasty, but with almost no side effects.”

L Lucas Wiegand, MD Reconstructive Urologist


Proven safe with challenging patients^{1,2}

In the ROBUST trials, patients who had experienced recurrent urethral strictures with one to four prior dilations, there were:

- **No late-onset treatment related events were observed²**
- **No impact on erectile function¹**

The results of this randomized controlled trial supports that Optilume® Stricture is safe and superior to standard direct vision internal urethrotomy/dilation for the treatment of recurrent anterior urethral strictures ≤3 cm in length.¹

Optilume® Stricture in action




Durable effectiveness, 5-year data¹

Optilume® Stricture delivers sustained relief due to paclitaxel's ability to limit fibrosis that leads to anterior urethral stricture.^{1,2}



72% freedom from repeat intervention at 5 years¹

Qmax flow rate increased from 5.0 mL/s at baseline to **19.9 mL/s¹**



IPSS Symptom Improvement

Average International Prostate Symptom Score (IPSS) improved from a mean of **25.2** at baseline to **7.2¹**



Post-void residual (PVR) Reduction

Average post-void residual was reduced from **141.4 mL** to **59.5 mL¹**

